PL2704701T3 - Związki do zastosowań związanych ze stanami zapalnymi i immunologicznymi - Google Patents

Związki do zastosowań związanych ze stanami zapalnymi i immunologicznymi

Info

Publication number
PL2704701T3
PL2704701T3 PL12779736T PL12779736T PL2704701T3 PL 2704701 T3 PL2704701 T3 PL 2704701T3 PL 12779736 T PL12779736 T PL 12779736T PL 12779736 T PL12779736 T PL 12779736T PL 2704701 T3 PL2704701 T3 PL 2704701T3
Authority
PL
Poland
Prior art keywords
inflammation
immune
compounds
related uses
Prior art date
Application number
PL12779736T
Other languages
English (en)
Inventor
Shoujun Chen
Gary Bohnert
Jun Jiang
Zhiqiang Xia
Original Assignee
PRCL Research Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PRCL Research Inc. filed Critical PRCL Research Inc.
Publication of PL2704701T3 publication Critical patent/PL2704701T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
PL12779736T 2011-05-03 2012-05-03 Związki do zastosowań związanych ze stanami zapalnymi i immunologicznymi PL2704701T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161481797P 2011-05-03 2011-05-03
US201161506403P 2011-07-11 2011-07-11
US201161552683P 2011-10-28 2011-10-28
US201161566870P 2011-12-05 2011-12-05
PCT/US2012/036241 WO2012151355A1 (en) 2011-05-03 2012-05-03 Compounds for inflammation and immune-related uses
EP12779736.3A EP2704701B1 (en) 2011-05-03 2012-05-03 Compounds for inflammation and immune-related uses

Publications (1)

Publication Number Publication Date
PL2704701T3 true PL2704701T3 (pl) 2018-06-29

Family

ID=47108043

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12779736T PL2704701T3 (pl) 2011-05-03 2012-05-03 Związki do zastosowań związanych ze stanami zapalnymi i immunologicznymi

Country Status (9)

Country Link
US (2) US9604978B2 (pl)
EP (1) EP2704701B1 (pl)
JP (1) JP5985611B2 (pl)
CN (1) CN103702665B (pl)
AU (1) AU2012250788B2 (pl)
CA (1) CA2834928C (pl)
ES (1) ES2660996T3 (pl)
PL (1) PL2704701T3 (pl)
WO (1) WO2012151355A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10703722B2 (en) 2010-04-27 2020-07-07 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2844655A1 (en) 2012-05-02 2015-03-11 Lupin Limited Substituted pyridine compounds as crac modulators
AU2013255441B2 (en) 2012-05-02 2017-11-09 Lupin Limited Substituted pyrazole compounds as CRAC modulators
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
US9725463B2 (en) 2013-06-21 2017-08-08 Lupin Limited Substituted heterocyclic compounds as CRAC modulators
EP3013810A1 (en) 2013-06-24 2016-05-04 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
EP2848615A1 (en) 2013-07-03 2015-03-18 Almirall, S.A. New pyrazole derivatives as CRAC channel modulators
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
US9663491B2 (en) * 2014-04-15 2017-05-30 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
CA2978823C (en) 2014-12-29 2023-10-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
TWI771269B (zh) 2015-02-27 2022-07-21 美商鈣系醫藥公司 胰腺炎治療
CA2995094A1 (en) * 2015-08-07 2017-02-16 Calcimedica, Inc. Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3172249A1 (en) 2020-03-20 2021-09-23 Calcimedica, Inc. Methods and compositions for treating acute lung injury and acute respiratory distress syndrome
JP7791898B2 (ja) 2020-11-13 2025-12-24 カルシメディカ,インク. Cracチャネル阻害剤の合成の改善
WO2024126777A1 (en) * 2022-12-16 2024-06-20 Astrazeneca Ab Heteroaromatic compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2525024A1 (de) * 1975-06-05 1976-12-30 Basf Ag 1,5-diphenylpyrazole und diese enthaltende arzneimittel
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
AU751139B2 (en) * 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
JP2000256358A (ja) * 1999-03-10 2000-09-19 Yamanouchi Pharmaceut Co Ltd ピラゾール誘導体
JP2001220390A (ja) * 2000-02-09 2001-08-14 Yamanouchi Pharmaceut Co Ltd 縮合ピラゾール誘導体
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
NZ545447A (en) 2003-07-23 2010-03-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
CA2585165A1 (en) * 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
WO2006083477A2 (en) * 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2006208045B2 (en) 2005-01-25 2012-08-30 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US20090131484A1 (en) * 2005-04-22 2009-05-21 Astellas Pharma Inc Preventive or remedy for bowel disease
JP2009524677A (ja) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
AU2007211276B2 (en) * 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
CA2645434A1 (en) * 2006-03-20 2007-09-27 Synta Pharmaceutical Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
WO2010039236A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP2350064A1 (en) * 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
AU2009300318A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
ES2512727T3 (es) * 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
US20140242099A1 (en) * 2011-10-28 2014-08-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses

Also Published As

Publication number Publication date
EP2704701B1 (en) 2018-01-03
US10399967B2 (en) 2019-09-03
JP5985611B2 (ja) 2016-09-06
CN103702665B (zh) 2016-08-17
AU2012250788B2 (en) 2017-03-02
US9604978B2 (en) 2017-03-28
CN103702665A (zh) 2014-04-02
ES2660996T3 (es) 2018-03-27
CA2834928C (en) 2017-10-17
WO2012151355A1 (en) 2012-11-08
AU2012250788A1 (en) 2013-12-19
US20170231984A1 (en) 2017-08-17
US20140171446A1 (en) 2014-06-19
JP2014513131A (ja) 2014-05-29
EP2704701A4 (en) 2014-10-29
EP2704701A1 (en) 2014-03-12
CA2834928A1 (en) 2012-11-08

Similar Documents

Publication Publication Date Title
EP2736330A4 (en) COMPOUNDS AND METHODS
IL233454A0 (en) Bromodomain inhibitors
IL230511A0 (en) 4-Imidazopyridazine-1-yl-benzamides and 4-imidazotriazine-1-yl-benzamides as btk inhibitors
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
IL230917A0 (en) 1dyrk inhibitors and uses thereof
EP2736329A4 (en) COMPOUNDS AND METHODS
GB201111705D0 (en) Compounds and their use
IL231082A0 (en) Pyrimido-pyridazinone compounds and their use
PT2568089T (pt) Utilização de um dispositivo de conexão de wc e de um wc de duche
EP2699670A4 (en) PARTICLES SYNTHETIZED FROM CELLS
GB201111775D0 (en) Compounds and uses thereof
GB201114448D0 (en) Compounds and their use
PL2794110T3 (pl) Granulator
PL2584028T3 (pl) Cząstka
GB201114855D0 (en) Compounds and their issues
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
LT3689878T (lt) 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk inhibitoriai
GB201120474D0 (en) Inhibitors
AU342498S (en) Spanner
AU342499S (en) Spanner
GB201104444D0 (en) Compounds and their use
GB201108290D0 (en) Solid supports
GB201103301D0 (en) Circair